RC2 CA148431/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2008	1
2009	3
2011	6
2012	5
2013	5
2014	2
2020	1
2021	1
2024	0

1

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.

Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Holkova B, et al. Leuk Lymphoma. 2021 May;62(5):1187-1194. doi: 10.1080/10428194.2020.1861270. Epub 2020 Dec 28. Leuk Lymphoma. 2021. PMID: 33356689 Free PMC article. Clinical Trial.

2

Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Bose P, Dai Y, Grant S. Bose P, et al. Pharmacol Ther. 2014 Sep;143(3):323-36. doi: 10.1016/j.pharmthera.2014.04.004. Epub 2014 Apr 24. Pharmacol Ther. 2014. PMID: 24769080 Free PMC article. Review.

3

Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism.

Nguyen TK, Grant S. Nguyen TK, et al. Mol Cancer Ther. 2014 Mar;13(3):662-74. doi: 10.1158/1535-7163.MCT-13-0714. Epub 2013 Dec 20. Mol Cancer Ther. 2014. PMID: 24362465 Free PMC article.

4

Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase.

Bose P, Park H, Al-Khafaji J, Grant S. Bose P, et al. Leuk Res Rep. 2013 Jan 1;2(1):18-20. doi: 10.1016/j.lrr.2013.02.001. Leuk Res Rep. 2013. PMID: 23977454 Free PMC article.

5

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

Bose P, Grant S. Bose P, et al. Leuk Res Rep. 2013 Jan 1;2(1):12-14. doi: 10.1016/j.lrr.2012.11.006. Leuk Res Rep. 2013. PMID: 23977453 Free PMC article.

6

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.

Bose P, Simmons GL, Grant S. Bose P, et al. Expert Opin Investig Drugs. 2013 Jun;22(6):723-38. doi: 10.1517/13543784.2013.789859. Epub 2013 May 6. Expert Opin Investig Drugs. 2013. PMID: 23647051 Free PMC article. Review.

7

Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.

Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S. Rahmani M, et al. Cancer Res. 2013 Feb 15;73(4):1340-51. doi: 10.1158/0008-5472.CAN-12-1365. Epub 2012 Dec 12. Cancer Res. 2013. PMID: 23243017 Free PMC article.

8

Proteasome inhibitors in mantle cell lymphoma.

Holkova B, Grant S. Holkova B, et al. Best Pract Res Clin Haematol. 2012 Jun;25(2):133-41. doi: 10.1016/j.beha.2012.04.007. Epub 2012 May 16. Best Pract Res Clin Haematol. 2012. PMID: 22687449 Free PMC article. Review.

9

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.

Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S. Rahmani M, et al. Blood. 2012 Jun 21;119(25):6089-98. doi: 10.1182/blood-2011-09-378141. Epub 2012 Mar 23. Blood. 2012. PMID: 22446485 Free PMC article.

10

LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

Rosato R, Hock S, Dent P, Dai Y, Grant S. Rosato R, et al. Leuk Res. 2012 Apr;36(4):491-8. doi: 10.1016/j.leukres.2011.10.020. Epub 2011 Nov 8. Leuk Res. 2012. PMID: 22074700 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

19 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year